Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ameren Corp (AEE) Earnings: 1 Dividend That’s Here to Stay

Page 1 of 2

Ameren Corp (NYSE:AEE) reported earnings this week, whiffing on revenue and underwhelming on earnings. But with a 4.8% dividend yield and a rate increase in the bag for 2013, now might be the perfect time to add Ameren to your portfolio. Let’s look at this quarter’s earnings and some longer-term trends and decide for ourselves whether Ameren is a buy.

On the top line, Ameren reported $1.5 billion in sales, down 4.4% from Q4 2011 and almost 15% below analyst expectations. But falling revenue is a sectorwide trend for utilities this quarter and is not necessarily reflective of a failing corporation.

Where Ameren’s earnings do hit hard is the company’s $0.14 EPS. Although this mirrors its Q4 2011 earnings, it comes in a whopping 30% below Mr. Market’s estimates.

For 2012 overall, Ameren recorded $2.42 in adjusted EPS, delivering on both its year-ago guidance range and its November 2012 estimate. These newest numbers are 5.5% below 2011’s earnings, primarily because of the utility’s merchant generation division.

From generation to regulation
There’s good news and bad news. The good news is that Ameren announced last December that it will exit the merchant generation business in 2013. The bad news is that the utility’s recording a $1.5 billion to $2 billion non-cash impairment charge to cut the cord. In 2012 alone, its generation adjusted earnings dropped more than 40% to $0.17 per share because of lower power prices and higher fuel costs. Rather than pouring profits into its five coal-fired and three gas-powered power plants, Ameren is bowing out and focusing entirely on its regulated business.

This radical move shows just how uncertain utilities are about which energy sources will win out. Once all the coal dust has settled, Duke Energy Corp (NYSE:DUK) will have spent around $12.5 billion in capital expenditures to modernize its out-of-date energy portfolio. Likewise, The Southern Company (NYSE:SO) Company recently navigated regulatory waters to win approval for two new nuclear reactors, the first such approval in more than 30 years.

Moving forward, an investment in Ameren will be an investment in this company’s regulatory environment. Historically, the utility has had mixed success in this department. In the past year, a $250 million annual rate increase in Missouri helped push its revenue higher, while lower allowed ROE and required nonrecoverable donations in Illinois pulled this state’s profits down. Ameren is going on the offensive in 2013, requesting a $50 million annual natural gas rate delivery increase for Illinois.

The utility is also taking a page out of American Electric Power Company, Inc. (NYSE:AEP)‘s playbook by focusing on its transmission division. Ameren is planning to invest $2.2 billion in the next four years to modernize its aging infrastructure. While it’s not as hefty as American’s $1.7 billion for 2012 alone, both utilities have recognized the benefit of investing in transmission.

Dividend dealing
Utilities have historically offered some of the most stable dividends around, but that’s all changing as companies dish out dollars to readjust their energy portfolios. Exelon Corporation (NYSE:EXC) recently announced that it’s cutting its dividend by 40% to clear cash for its nuclear and renewable-energy investments.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!